{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "VKTX",
  "name": "Viking Therapeutics, Inc.",
  "url": "https://orbyd.app/dossiers/VKTX/",
  "json_url": "https://orbyd.app/dossiers/VKTX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Last large independent GLP-1/GIP obesity asset and a live M&A target, but VANQUISH pivotal topline is a 2027 event — a catalyst vacuum bridged only by a 3Q26 maintenance-dose readout. Tape rolling over from ~$40 (07-09) to ~$35.50 (07-25), losing the high-$30s shelf into a 2026-07-29 Q2 print with no pipeline data to cushion it.",
  "invalidation_trigger": "A weekly close below $34 forfeits the July base beneath the broken high-$30s shelf and opens the low-$30s/mid-$20s; a 3Q26 subcutaneous maintenance-dose miss or a VANQUISH completion slip announced beyond 2027 confirms the near-term leg is dead.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q1 2026 cash $603M, runway guided through 2028; no forced raise expected, but Q1 net loss widened to -$158.3M / -$1.37 (missed by 34%).",
    "Q2 2026 earnings date is estimated (~late July) — confirm exact date before treating the ~2026-07-29 catalyst as firm.",
    "Q2 2026 earnings confirmed 2026-07-29 after market close (4:30pm ET call); no revenue, Zacks est -$1.21 EPS; missed each of trailing 4 quarters (avg ~-36.7% surprise). Binary risk into a print that is not the thesis driver — avoid fresh entries into it.",
    "VANQUISH-1 (enrolled Nov 2025, ~4,650 adults) and VANQUISH-2 (enrolled 2026-03-26, ~1,000 adults) both carry a 78-week primary endpoint; company frames completion as a 2027 event. No pivotal efficacy binary before 2027.",
    "3Q26 is the live near-term window: VK2735 subcutaneous maintenance-dose topline + VK3019 (dual amylin/calcitonin) Phase 1 initial data. Oral maintenance guided 1H27; oral Phase 3 start 4Q26. Watch the 07-29 call for exact dating.",
    "Q1 2026 cash ~$603M, runway guided into 2028; no forced raise expected.",
    "M&A optionality: Vertex/~$10B Crinetics deal (May 2026) refocused takeover attention; prediction-market implied ~38.5% acquisition-before-2027 probability. Analyst avg PT ~$94.62, 17/18 Buy vs ~$35.50 tape.",
    "Price lost the high-$30s shelf ($36–$40); ~$34 is the immediate line, then a gap toward low-$30s and the $22.96 52-week low. 52-week high $43.15."
  ],
  "body_markdown": "## Current Thesis\nViking is the last large independent GLP-1/GIP obesity asset and a live M&A target, but the setup right now is a heavy tape into a binary print, not a run. VK2735 — the dual agonist in subcutaneous and oral form — has VANQUISH-1 (enrolled November 2025) and VANQUISH-2 (enrolled 2026-03-26) both fully enrolled, yet both carry a 78-week primary endpoint and the company frames completion as a 2027 event. There is no efficacy binary before then. The back half of 2026 is a catalyst vacuum bridged only by a 3Q26 subcutaneous maintenance-dose readout and VK3019 Phase 1 initial data. The narrative an investor buys is \"best independent efficacy plus buyout premium into 2027 pivotal data.\" The problem: the stock fell from ~$40 (2026-07-09) to ~$35.50 (2026-07-25), losing the high-$30s shelf that had capped it since the May ECO data, and Q2 earnings land 2026-07-29 with no pipeline data to cushion the print. The obesity theme is mature and crowded, and the price structure is rolling over. This is a name to stand aside on until it bases and the maintenance-dose window opens — chasing it into the print is binary risk, not edge.\n\n## Bull Case\n- **Best efficacy among independents.** Phase 2 VENTURE-Oral data at ECO 2026 (2026-05-12) showed up to 12.2% mean weight loss at Week 13 on the top oral dose — competitive with injectable-class results and ahead of Lilly's oral orforglipron on raw magnitude.\n- **Pivotals de-risked operationally.** VANQUISH-1 (~4,650 adults, enrolled November 2025) and VANQUISH-2 (~1,000 adults, 78-week primary plus a 52-week extension, enrolled 2026-03-26) are both fully enrolled; execution risk is off the table and only the efficacy readout remains.\n- **M&A optionality is intensifying.** Vertex's ~$10B Crinetics deal (May 2026) refocused takeover attention on Viking as the cleanest independent obesity bolt-on; prediction-market data implies roughly a 38.5% probability of acquisition before 2027.\n- **Cash covers the war.** Q1 2026 left ~$603M in cash with runway guided into 2028 — Viking funds both VANQUISH studies and the 4Q26 oral Phase 3 start without a forced raise.\n- **Analyst gap is wide.** 17 of 18 analysts rate Buy with an average target near $94.62 versus a ~$35.50 tape (2026-07-25); the spread is the buyout and pivotal-data option value.\n- **Pipeline is broadening.** VK3019, a dual amylin/calcitonin agonist, entered Phase 1 ascending-dose dosing on 2026-06-24 with initial data guided to 3Q26 — an optionality leg on the amylin mechanism Lilly and Novo are also chasing.\n\n## Bear Case\n- **The catalyst vacuum is the whole structure.** The move-the-stock binary — VANQUISH topline — is a 2027 event; nothing before then is pivotal, and a fully-enrolled name can dead-money-drift for four-plus quarters.\n- **Price is rolling over.** Down ~11% from ~$40 (2026-07-09) to ~$35.50 (2026-07-25), the stock lost the high-$30s consolidation shelf ($36–$40) and now trades near its recent intraday low of $34.41.\n- **Earnings land into weakness with no data to offset.** Q2 prints 2026-07-29 after close; the Zacks estimate is a -$1.21 loss, and Viking has missed each of the trailing four quarters (average surprise ~-36.7%). A binary print with no pipeline catalyst underneath it.\n- **The theme has gone mainstream.** GLP-1/obesity is front-page — Lilly (Zepbound, orforglipron), Novo (Wegovy) and Pfizer all crowd the shelf. When the leaders own the story, the challenger's re-rate slows.\n- **Oral competition is the overhang.** Lilly's orforglipron manufacturing and scale lead means VK2735 oral must prove not just efficacy but supply — a bar a mid-cap struggles to clear alone.\n- **Burn keeps widening.** R&D near $150M per quarter feeds a widening loss with zero product revenue to absorb it.\n\n## Setup & Price Structure\nTrading ~$35.50 as of 2026-07-25, inside that session's $34.41–$35.92 range. The 52-week high is $43.15 and the 52-week low $22.96. The high-$30s shelf ($36–$40) that had capped the name since the May ECO oral data is now broken, and there is no dated near-term pivotal to force a reversal — the next efficacy binary is a 2027 topline. This is a maturing structure breaking lower, absent the strength a momentum entry requires. Immediate support sits near $34 (the recent intraday low); below it, a gap opens toward the low-$30s and, further out, the mid-$20s 52-week low. To the upside, reclaiming $40 puts the $43.15 high back in play, but that needs a fresh catalyst the calendar does not offer before the maintenance-dose window. Standing aside until it bases is the disciplined read; the July semiconductor-led Nasdaq drawdown (2026-07-07/08) already pulled high-beta biotech lower and Viking traded with it.\n\n## Catalyst Calendar (next 30 days)\n\n- **3Q26 window (~Aug–Sept, beyond 30d but the next real binary):** subcutaneous VK2735 maintenance-dose topline; VK3019 Phase 1 initial data. Exact dates unannounced — watch for scheduling on the 07-29 call.\n- **4Q26 (beyond 30d):** oral VK2735 Phase 3 program initiation; oral maintenance results guided to 1H27.\n- No FDA/PDUFA date is pending. VANQUISH-1/VANQUISH-2 topline is a 2027 event.\n\n## Elapsed catalysts\n\n- **2026-07-29 (confirmed):** Q2 2026 earnings after market close, 4:30pm ET call. Zacks estimate -$1.21 EPS; no product revenue. The driver is pipeline commentary — VANQUISH progress, exact 3Q26 subcutaneous maintenance-dose timing, oral Phase 3 4Q26 start, and any VK3019 update. Binary print; avoid fresh entries into it. *(passed 11d ago)*\n\n## What Would Change Our Mind\n- **Upside re-establishment:** a weekly close reclaiming $40, ideally alongside a maintenance-dose beat or a confirmed M&A approach, restores the accelerating leg and turns a base into a breakout retest worth sizing.\n- **Downside confirmation:** a weekly close below $34 forfeits the current base beneath the broken high-$30s shelf and opens the low-$30s and mid-$20s; a subcutaneous maintenance-dose miss in 3Q26 or a VANQUISH completion slip announced beyond 2027 kills the near-term thesis outright.\n- **Theme flip:** obesity coverage going fully saturated with Lilly and Novo owning the oral narrative removes the challenger premium and drains the M&A bid.\n\n## Correlation Notes\n- **Obesity/GLP-1 complex:** trades with LLY and NVO as the leaders; re-rates on their trial and regulatory headlines. A Lilly oral orforglipron beat pressures VK2735's differentiation; a Lilly or Novo stumble is a direct tailwind for the independent challenger.\n- **Small/mid-cap biotech beta:** high sensitivity to XBI/IBB risk appetite and rates. The 2026-07-07/08 semiconductor-led Nasdaq drawdown dragged high-beta names including VKTX regardless of company-specific news.\n- **M&A-basket sentiment:** re-rates with obesity-takeover appetite (post Vertex/Crinetics). Around the 2026-07-29 print and the 3Q26 readouts, idiosyncratic single-stock risk dominates the correlations above.",
  "first_seen": "2026-07-10",
  "last_analyzed": "2026-07-26T12:43:46+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}